EGFR and congenital rubella syndrome: In order to induce the death of CAR-T cells co-expressing EGFRt after transfusion into the body in the case of CRS side effects, cetuximab, an anti-EGFR mAb, can be administrated, which will stimulate antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity [11,24,25].